title: New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors.
abstract: The prognosis of adult acute lymphoblastic leukemia (ALL) remains poor and novel treatment strategies are needed. Antibody-based therapies represent such an approach. ALL cells express various surface antigens that are targets for monoclonal antibodies. This review focuses on 4 major classes of antibody therapy: (1) naked antibodies, (2) T-cell-engaging bispecific single-chain antibodies, (3) immunoconjugates/immunotoxins, and (4) chimeric antigen receptors. Preclinical and clinical data are reviewed. This area of research represents an exciting new approach to help improve the outcome of this disease. Several clinical trials are currently incorporating this therapy in the treatment of newly diagnosed and relapsed adult ALL patients.
authors: 1Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, and.
authors: Anjali S
authors: AS
authors: Advani
mesh_terms: D000328:Adult; D000912:Antibodies, Neoplasm / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000235:genetics / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D011946:Receptors, Antigen / Q000235:genetics / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000627:therapeutic use*; D057127:Single-Chain Antibodies / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D000912:Antibodies, Neoplasm; D018796:Immunoconjugates; D011946:Receptors, Antigen; D011993:Recombinant Fusion Proteins; D057127:Single-Chain Antibodies